JP2020533276A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533276A5
JP2020533276A5 JP2020505478A JP2020505478A JP2020533276A5 JP 2020533276 A5 JP2020533276 A5 JP 2020533276A5 JP 2020505478 A JP2020505478 A JP 2020505478A JP 2020505478 A JP2020505478 A JP 2020505478A JP 2020533276 A5 JP2020533276 A5 JP 2020533276A5
Authority
JP
Japan
Prior art keywords
composition
raav vector
nucleic acid
aav
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020505478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533276A (ja
JP7499174B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044892 external-priority patent/WO2019028192A1/en
Publication of JP2020533276A publication Critical patent/JP2020533276A/ja
Publication of JP2020533276A5 publication Critical patent/JP2020533276A5/ja
Application granted granted Critical
Publication of JP7499174B2 publication Critical patent/JP7499174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020505478A 2017-08-01 2018-08-01 第viii因子(fviii)遺伝子治療法 Active JP7499174B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762540053P 2017-08-01 2017-08-01
US62/540,053 2017-08-01
US201762583890P 2017-11-09 2017-11-09
US62/583,890 2017-11-09
US201762596535P 2017-12-08 2017-12-08
US201762596670P 2017-12-08 2017-12-08
US62/596,535 2017-12-08
US62/596,670 2017-12-08
PCT/US2018/044892 WO2019028192A1 (en) 2017-08-01 2018-08-01 METHODS OF GENE THERAPY TARGETING FACTOR VIII (FVIII)

Publications (3)

Publication Number Publication Date
JP2020533276A JP2020533276A (ja) 2020-11-19
JP2020533276A5 true JP2020533276A5 (https=) 2021-11-25
JP7499174B2 JP7499174B2 (ja) 2024-06-13

Family

ID=65234171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505478A Active JP7499174B2 (ja) 2017-08-01 2018-08-01 第viii因子(fviii)遺伝子治療法

Country Status (17)

Country Link
US (1) US20200237930A1 (https=)
EP (1) EP3661541A4 (https=)
JP (1) JP7499174B2 (https=)
KR (2) KR20200066289A (https=)
CN (1) CN111163796A (https=)
AU (2) AU2018312565A1 (https=)
BR (1) BR112020001979A2 (https=)
CA (1) CA3071519A1 (https=)
CL (1) CL2020000295A1 (https=)
CO (1) CO2020002283A2 (https=)
IL (1) IL272373A (https=)
MX (1) MX2020001402A (https=)
MY (1) MY208862A (https=)
PE (1) PE20200722A1 (https=)
PH (1) PH12020500239A1 (https=)
SG (1) SG11202000650YA (https=)
WO (1) WO2019028192A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
JP2021509812A (ja) 2018-01-05 2021-04-08 プレートレット バイオジェネシス, インコーポレイテッド 巨核球を産生するための組成物および方法
AU2019291955A1 (en) 2018-06-29 2021-02-18 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
WO2020028830A1 (en) * 2018-08-03 2020-02-06 Sangamo Therapeutics, Inc. Improved clinical parameters by expression of factor viii
US11529427B2 (en) 2019-02-15 2022-12-20 Crispr Therapeutics Ag Gene editing for hemophilia A with improved factor VIII expression
WO2020186207A2 (en) 2019-03-13 2020-09-17 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing fviii therapeutics
CN110684798A (zh) * 2019-09-03 2020-01-14 深圳新诺微环生物科技有限公司 肌肉靶向的微环dna基因治疗
EP4051704A2 (en) * 2019-11-01 2022-09-07 Freeline Therapeutics Limited Factor viii construct
WO2021113800A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法
CN115948408A (zh) * 2022-09-23 2023-04-11 上海信致医药科技有限公司 改进的人凝血因子viii基因表达盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU7879000A (en) * 1999-10-12 2001-04-23 University Of North Carolina At Chapel Hill, The Adeno-associated virus vectors encoding factor viii and methods of using the same
RS61039B1 (sr) * 2013-09-12 2020-12-31 Biomarin Pharm Inc Aav vektori koji sadrže gen koji kodira faktor viii
CA3237630A1 (en) * 2014-08-13 2016-02-18 The Children's Hospital Of Philadelphia An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
CN115074366A (zh) * 2015-04-16 2022-09-20 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
RU2742352C2 (ru) * 2015-09-24 2021-02-05 Байомарин Фармасьютикал Инк. Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
CA3002524A1 (en) * 2015-10-28 2017-05-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor viii expression cassettes and methods of use thereof
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
US20190144524A1 (en) * 2016-01-14 2019-05-16 The Children's Hospital Of Philadelphia Factor viii variants, nucleic acid sequences, and methods and uses for treatment of hemostasis disorders

Similar Documents

Publication Publication Date Title
JP2020533276A5 (https=)
RU2018119710A (ru) Кодирующие фактор viii варианты с пониженным содержанием cpg, композиции и способы, и применение в лечении нарушений гемостаза
JP2021003120A5 (https=)
JP7493566B2 (ja) 筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
JP2019503649A5 (https=)
JP2024009857A5 (https=)
JP2021087431A5 (https=)
JP2019116492A5 (https=)
JP2018506261A5 (https=)
JP2021106619A5 (https=)
JP2021533805A5 (https=)
JP2018522529A5 (https=)
TW201840850A (zh) 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症
JP2020522269A5 (https=)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2018531609A5 (https=)
US20210198692A1 (en) Adeno-associated viral vector-mediated gene therapy for treating fragile x-associated disorders
US20040002159A1 (en) Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof
JP2017529395A5 (https=)
JP2021511020A5 (https=)
JPWO2020041773A5 (https=)
JPWO2020186207A5 (https=)
JPWO2020186150A5 (https=)
RU2020108209A (ru) Способы генотерапии с использованием гена фактора viii (fviii)
NZ741860B2 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders